Clinical Trial: NCT06812871
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2026-08-14 |
Study Overview
Brief Summary
the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
Official Title
A Single-arm, Multicenter, Phase 2 Study of High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Conditions
Non-small Cell Lung Cancer Metastatic
Intervention / Treatment
- Drug: furmonertinib
Other Study ID Numbers
- GASTO 10120
Start Date (Actual)
2024-01-01
Primary Completion Date (Actual)
2026-03-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
46
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2026-08-14 |
Study Overview
Brief Summary
the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
Official Title
A Single-arm, Multicenter, Phase 2 Study of High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Conditions
Non-small Cell Lung Cancer Metastatic
Intervention / Treatment
- Drug: furmonertinib
Other Study ID Numbers
- GASTO 10120
Start Date (Actual)
2024-01-01
Primary Completion Date (Actual)
2026-03-30
Study Completion Date (Actual)
2026-06-30
Enrollment (Actual)
46
Study Type
Interventional
Phase
Phase 2